Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01137006 · ClinicalTrials.gov registry record · Phase 1
An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
A Phase 1 study of Malignant Melanoma, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 2
- Study locations
NCT01137006 is a Phase 1 study of Malignant Melanoma that has completed, run by Eli Lilly and Company. The registered enrollment target is 27 participants, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01137006, a Phase 1 study of Malignant Melanoma, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 2
- Study locations
Study Summary
A dose-escalation study designed to determine the safety, maximum tolerated dose (MTD), anti-melanoma activity, antibody blood levels and progression-free survival (PFS) in participants with malignant melanoma receiving IMC-20D7S either every 2 weeks or every 3 weeks.
Conditions Studied
Interventions
- BIOLOGICAL IMC-20D7S (Cohort 1A)
- BIOLOGICAL IMC-20D7S (Cohort 2A)
- BIOLOGICAL IMC-20D7S (Cohort 3A)
- BIOLOGICAL IMC-20D7S (Cohort 4A)
- BIOLOGICAL IMC-20D7S (Cohort 1B)
Study Locations (2)
Massachusetts
- ImClone Investigational Site - Boston
New York
- ImClone Investigational Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01137006
The ClinicalTrials.gov registry entry for NCT01137006 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (85% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 5 interventions - of which IMC-20D7S (Cohort 1A) is the first listed.
NCT01137006 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT01137006 about?
NCT01137006 is a clinical study titled "An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma". A dose-escalation study designed to determine the safety, maximum tolerated dose (MTD), anti-melanoma activity, antibody blood levels and progression-free survival (PFS) in participants with malignant melanoma receiving IMC-20D7S either every 2 weeks or every 3 weeks.
What is the current status of trial NCT01137006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-06. Estimated completion is 2012-08.
What conditions does trial NCT01137006 study?
This clinical trial studies the following conditions: Malignant Melanoma.
What interventions are being tested in trial NCT01137006?
The interventions under investigation include: IMC-20D7S (Cohort 1A) (BIOLOGICAL), IMC-20D7S (Cohort 2A) (BIOLOGICAL), IMC-20D7S (Cohort 3A) (BIOLOGICAL), IMC-20D7S (Cohort 4A) (BIOLOGICAL), IMC-20D7S (Cohort 1B) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01137006?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01137006 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
-
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RECRUITING · Phase 1
-
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.